Proposed acquisition offerspotentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases, Expands innovative pipeline potentially enhancing growth through 2025 and beyond, Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion, Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc. Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. How many employees does Arena Pharmaceuticals have? Pfizer Inc. invites Pfizer investors and the general public to view and listen to a webcast of a live conference call with investment analysts at 10am. Export data to Excel for your own analysis. View contacts for Arena Pharmaceuticals to access new leads and connect with decision-makers. Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. The password is 121321. Please join the call five minutes prior to the start time to avoid operator hold times. The P/E ratio of Arena Pharmaceuticals is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Arenas portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including gastrointestinal and dermatological diseases. Arena is also researching temanogrel to determine its impact on Raynaud's phenomenon that's caused by systemic sclerosis.
The acquisition is a follow-up to another buyout in which Pfizer purchased blood cancer treatment company Trillium Therapeutics for more than $2.2 billion. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. Receive ARNA Stock News and Ratings via Email, February 9, 2022|markets.businessinsider.com. View ARNA analyst ratings or view top-rated stocks. See disclosure
Arena Pharmaceuticals - Crunchbase Company Profile & Funding $ARNA up 93% #premarket. The Arena acquisition will help Pfizer deliver a more effective and robust treatment solution than it might have otherwise been able to achieve. There are currently 10 hold ratings for the stock. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.
Arena Pharmaceuticals Patrick Malloy The acquisition was completed by way of a merger in accordance with Delaware law and, as a result of the acquisition, Arena became a wholly-owned subsidiary of Pfizer.
5 were here. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion. They are headquartered in San Diego, CA. The information contained in this release is as of December 13, 2021. "(Arena) was our top pick for 2022, so Christmas came a bit early We would not expect another bidder to come in at this point," said Wells Fargo analyst Derek Archila. How were Arena Pharmaceuticals' earnings last quarter? Arena Pharmaceuticals (NASDAQ:ARNA) has a market capitalization of $6.17 billion and generates $50,000.00 in revenue each year. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SECs web site at www.sec.gov, on Arenas website at https://invest.arenapharm.com or by contacting Arena Investor Relations at (858) 453-7200. The proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology, a Pfizer innovation engine developing potential therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options, said Mike Gladstone, Global President & General Manager, Pfizer Inflammation and Immunology.
Pfizer to Acquire Arena Pharmaceuticals - Yahoo! Pfizer said on Monday it would buy drug developer Arena Pharmaceuticals for $6.7 billion in cash, to add a promising treatment candidate that targets diseases affecting the stomach and intestine.
This is largely seen as a positive for Pfizer, given Arenas robust drug Pfizer is entering the medical cannabis industry by acquiring Arena Pharmaceuticals and its promising cannabinoid-based bowel disease treatment. Arena Pharmaceuticals was founded in 1977. What is Arena Pharmaceuticals' official website? The official website for Arena Pharmaceuticals is www.arenapharm.com. Where are Arena Pharmaceuticals' headquarters? Arena Pharmaceuticals is headquartered at 6154 Nancy Ridge Drive, San Diego CA, 92121. Today, after a successful phase 2 trial on a rare lung disease treatment, Arena Pharmaceuticals jumped almost 45% to just under $28. Can Activision Blizzard Rally Into Year End? High institutional ownership can be a signal of strong market trust in this company. Contact Email invest@arenapharm.com. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. 2022 Forbes Media LLC.
Arena Pharmaceuticals: A Speculative Buy Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T). The definitive proxy statement will be mailed to Arenas stockholders in connection with the proposed transaction. Want to see which stocks are moving? According to analysts' consensus price target of $96.38, Arena Pharmaceuticals has a forecasted downside of 3.6% from its current price of $99.99. Arena Pharmaceuticals's revenue growth from 2016 to 2020 is -99.65%. YouTube, American Consumer News, LLC dba MarketBeat 2010-2022. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Analysts are expecting a loss of 10 cents per share, down from a loss of nine cents per share a year ago.The consensus estimate hasn't changed over the [], After Arena Pharmaceuticalsexperienced a loss of 10 cents a year ago, analysts predict positive news when the company reports this year's fourth quarter numbers on Thursday, February 27, 2014.
Pfizer to acquire Arena Pharmaceuticals in $6.7 billion Here's what Arena Pharmaceuticals is focusing on in its pipeline, and why the funds from the Pfizer buyout could put drug developments in the fast lane. Participants in the Solicitation Did The Smart Money Play Arena Pharmaceuticals, Inc. (ARNA) Correctly?
The Stilly Diner | American Restaurant in Arlington, WA For more than 170 years, we have worked to make a difference for all who rely on us. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.
Haggen Pharmacy - Immunizations & Vaccinations | Haggen After extensive research and analysis, Zippia's data science team found the following key financial metrics. Participants are advised to pre-register in advance of the conference call. All rights reserved. For more than 170 years, we have worked to make a difference for all who rely on us. Investors & Media: NEW YORK, March 11, 2022--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA.". Arena Pharmaceuticals has 194 employees, and the revenue per employee ratio is $1,644. This is the latest deal Pfizer has struck this year to expand its treatment pipeline. +1 (212) 733-1226[emailprotected], Pfizer Investors: Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; negative effects of the consummation of the acquisition on the market price of Pfizers common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the acquisition or Arenas business; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for etrasimod, temanogrel, APD418 or any other investigational products; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether etrasimod, temanogrel, APD418 or any such other products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of etrasimod, temanogrel, APD418 or any such other products; uncertainties regarding the impact of COVID-19; and competitive developments. About Pfizer Inflammation & ImmunologyAt Pfizer Inflammation & Immunology, we strive to deliver breakthroughs that enable freedom from day-to-day suffering for people living with autoimmune and chronic inflammatory diseases, which can be debilitating, disfiguring and distressing, dramatically affecting what they can do. Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and By creating a free account, you agree to our, VP of Investor Relations & Corp. Communications. Is Pfizer's Acquisition of Arena a Good Move for Investors? View analysts price targets for ARNA or view top-rated stocks among Wall Street analysts. Identify stocks that meet your criteria using seven unique stock screeners. The biopharmaceutical company can be reached via phone at (858) 453-7200, via email at [emailprotected], or via fax at 858-453-7210. Arena Pharmaceuticals has a P/B Ratio of 9.14. Pfizer has concluded the takeover of the complete outstanding shares, options and restricted stock units of clinical-stage firm Arena Pharmaceuticals for an equity price of nearly For additional background on the acquisition, please read the announcement press release here. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. The transcript and webcast replay of the call will be made available on Pfizers web site at www.pfizer.com/investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.
Arena Pharmaceuticals Arena Got a confidential news tip? A person walks past the Pfizer Headquarters building in New York, November 9, 2020. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. Arena Pharmaceuticals (NASDAQ:ARNA) has a market capitalization of $6.17 billion and generates $50,000.00 in revenue each year. Will Pfizer Stock See Higher Levels After A 10% Rise In A Month? What is Arena Pharmaceuticals' stock price forecast for 2023? +1 (847) 987-4878[emailprotected], Sara Doran Should investors sell to lock in gains, or hold on? ARNA | Complete Arwana Citramulia stock news by MarketWatch. Data is a real-time snapshot *Data is delayed at least 15 minutes. Jim Cramer: Dr. Scott Gottlieb's latest omicron warning is 'a major wake-up call'. Our mobile app makes it easy to order refills, view your familys prescriptions and available refills, or even get reminders when its time to take your medication.
Pfizer Completes Acquisition of Arena Pharmaceuticals Are Options Traders Betting on a Big Move in Arena (ARNA) Stock?
Arena Pharmaceuticals | ARNA Stock Price, Company The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by Arenas stockholders. The $100 per share offer is double the last closing price of Arena's shares, which surged 92% to $95.90 in premarket trading. Earnings for Arena Pharmaceuticals are expected to grow in the coming year, from ($8.32) to ($6.78) per share. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Pfizer and Arena described in the Risk Factors and Forward-Looking Information and Factors That May Affect Future Results sections of their respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed by either of them from time to time with the U.S. Securities and Exchange Commission (the SEC), all of which are available at www.sec.gov. Any vote in respect of resolutions to be proposed at Arenas stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in Arenas proxy statement. Company Type For Profit. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed.
16 employees have rated Arena Pharmaceuticals Chief Executive Officer Amit Munshi on Glassdoor.com.
Pfizer to Acquire Arena Pharmaceuticals | Pfizer Pfizer concludes Arena Pharmaceuticals acquisition for $6.7bn Legal Name Arena Pharmaceuticals, Inc. Stock Symbol NASDAQ:ARNA. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. In connection with the acquisition, Arenas shares of common stock will be delisted from the Nasdaq Global Select Market on or about March 11, 2022. This release contains forward-looking information about Pfizers proposed acquisition of Arena, Arenas pipeline portfolio, including its molecules etrasimod, temanogrel and APD418 and expected best-in-class and growth potential, and Pfizers I&I portfolio and growth potential, including their potential benefits, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The disease is rare but recurring and painful. 99.99 (0.06%) 3rd Party Ad. Additional Information and Where to Find It Get short term trading ideas from the MarketBeat Idea Engine. Arena is experimenting with a drug RIST4721 for applications like inflammatory bowel disease and PPP (palmoplantar pustulosis). ARENA Pharmaceuticals is a team with a singular purpose deliver important medicines to patients. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. Active, Closed, Last funding round type (e.g. +1 (212) 733-4848[emailprotected], Arena Phone Number 858-453-7200. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 89 days until expiration the newly available contracts [], Investors considering a purchase of Arena Pharmaceuticals Inc (NASD: ARNA) shares, but cautious about paying the going market price of $8.89/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ARNA Stock Price | Arwana Citramulia Stock Quote (Indonesia: Communications[emailprotected]. The consensus among Wall Street analysts is that investors should "hold" Arena Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares. View analyst ratings for Arena Pharmaceuticals or view top-rated stocks. Temanogrel is a phase two drug working to treat microvascular obstruction, which causes damage or dysfunction in parts of the coronary circulation network after occluded coronary artery reperfusion. Integral Health Asset Management, LLC Buys McKesson Corp, Centene Corp, Abbott Laboratories. Its lead candidate, etrasimod, is being tested in a late-stage study in ulcerative colitis, as well as a mid-to-late stage study in Crohn's disease, both types of inflammatory bowel diseases that cause ulcers in the digestive tract. Looking for new stock ideas? Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Arena Pharmaceuticals, Inc. Company Profile | Park City, UT These documents are available free of charge at the SECs web site at www.sec.gov and by going to Arenas website at https://invest.arenapharm.com. Pfizers capabilities will accelerate our mission to deliver our important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. GlobalFoundries Pops Nearly 9% On Better-Than-Expected Q3 Results, Two Green Energy Plays Poised For Gains In 2023, Mullen Automotive: Momentum Builds, Bears Risk Short-Squeeze, The Cheesecake Factory Shows You Can Have It and Eat It Too, Two EV Stocks That Could Rally Into Year-End. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares. Pfizer expects to finance the transaction with existing cash on hand. Pfizer Completes Acquisition of Arena Pharmaceuticals. $PFE up 1%. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Etrasimod also treats eosinophilic esophagitis, which is a disease that causes white blood cells to build up in the lining of the esophagus. Why Arena Pharmaceuticals Stock Is Soaring Today msn.com - December 13 at 12:24 PM: Arena Pharmaceuticals Shares Surge on Takeover by Pfizer >ARNA marketwatch.com - December 13 at 12:24 PM: Arena Pharmaceuticals soars 97% as Pfizer to spend $6.7 billion to buy ulcerative colitis drug developer msn.com - December 13 at 12:24 PM Arena Pharmaceuticals does not have a long track record of dividend growth. Analysts are expecting a loss of 13 cents per share, down from a loss of 11 cents per share a year ago.Analysts are projecting a loss of 26 [], Arena Pharmaceuticals is expected to book a wider loss than a year ago when it reports third-quarter earnings on Monday, November 3, 2014. On average, they anticipate the company's share price to reach $96.38 in the next twelve months. Arena's top treatment currently in the pipeline is called etrasimod. Not an offer or recommendation by Stocktwits. Arena Pharmaceuticals revenue is $319.0K annually. (Raynaud's phenomenon is one type of Raynaud's that's caused by an underlying conditionin this case, systemic sclerosis.). 83.77% of the stock of Arena Pharmaceuticals is held by institutions. Amit Munshi has an approval rating of 66% among the company's employees. This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. "The proposed acquisition of Arena complements our capabilities and expertise in inflammation and immunology," Pfizer executive Mike Gladstone said, adding the company plans to accelerate the clinical development of etrasimod. Like Arena, Pfizer has an ulcerative colitis treatment in the works. View real-time stock prices and stock quotes for a full financial overview. Analysts are expecting a loss of 13 cents per share, down from a loss of eight cents per share a year ago.The consensus estimate hasn't changed over [], When Arena Pharmaceuticalsreports its second quarter results on Friday, August 1, 2014, analysts are anticipating a drop into the red. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. What is Arena Pharmaceuticals' stock symbol? Pfizer plans to purchase San Diego-based Arena Pharmaceuticals Inc. for $6.7 billion (entirely in cash, no less). Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. The biopharmaceutical company earns $-616,430,000.00 in net income (profit) each year or ($10.13) on an earnings per share basis. Get daily stock ideas from top-performing Wall Street analysts. During the same period last year, the company earned ($1.69) EPS.